{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:11:50Z","timestamp":1771297910582,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The flare phenomenon is a transient increase in the number or intensity of lesions on bone scans after treatment, signifying curative effect. DOTA-ibandronic acid (DOTA-IBA) is a new prodrug that targets bone metastases and can be labeled with <jats:sup>177<\/jats:sup>Lu. Here, we report the case of a 58-year-old woman with bone metastasis, in whom the flare phenomenon was observed after 4 cycles of <jats:sup>177<\/jats:sup>Lu-DOTA-IBA treatment. No adverse effects were observed during the treatment and follow-up periods.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005303","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T05:00:46Z","timestamp":1718686846000},"page":"793-796","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Flare Phenomenon After 177Lu-DOTA-IBA Therapy in Bone Metastases of Lung Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Qingchu","family":"Hua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengcuo","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and efficacy of 68Ga- or 177Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases : a phase 0\/I study","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","year":"2023","journal-title":"Mol Pharm"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/RLU.0b013e3181a344df","article-title":"Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib","volume":"34","year":"2009","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/cancers14010254","article-title":"Reliability of alkaline phosphatase for differentiating flare phenomenon from disease progression with bone scintigraphy","volume":"14","year":"2022","journal-title":"Cancer"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2016.03.002","article-title":"Radium-223 in heavily pretreated metastatic castrate-resistant prostate cancer","volume":"14","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/RLU.0000000000004107","article-title":"Bone and lymph node flare to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer on 18F-prostate-specific membrane antigen PET\/CT with decreasing prostate-specific antigen of 0.7 ng\/mL","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"100623","DOI":"10.1016\/j.adro.2020.11.008","article-title":"Lutetium Lu-177 Dotatate flare reaction","volume":"6","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00259-018-3947-x","article-title":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000000290","article-title":"Targeted \u03b1-particle therapy of bone metastases in prostate cancer","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2967\/jnumed.112.112482","article-title":"Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: \u03b1 therapy with 223Ra-dichloride","volume":"55","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:00:44Z","timestamp":1750532444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005303","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}